Endocrinology
| Study name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| Redefine 2 | "Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity and type 2 diabetes" | Clinical Trial (NCT05394519) | Novo Nordisk | Commercial: Industry |
| Redefine 3 | The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease | Clinical Trial (NCT05669755) | Novo Nordisk | Commercial: Industry |
| PKD Registry | Pyruvate Kinase Deficiency Global Longitudinal Registry | Clinical Trial (NCTO3481738) | Agios | Commercial : Industry |